Hypersensitivity - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hypersensitivity - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hypersensitivity - Pipeline Review, H2 2015', provides an overview of the Hypersensitivity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hypersensitivity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hypersensitivity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypersensitivity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypersensitivity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypersensitivity Overview 6
Therapeutics Development 7
Pipeline Products for Hypersensitivity - Overview 7
Pipeline Products for Hypersensitivity - Comparative Analysis 8
Hypersensitivity - Therapeutics under Development by Companies 9
Hypersensitivity - Therapeutics under Investigation by Universities/Institutes 10
Hypersensitivity - Pipeline Products Glance 11
Early Stage Products 11
Hypersensitivity - Products under Development by Companies 12
Hypersensitivity - Products under Investigation by Universities/Institutes 13
Hypersensitivity - Companies Involved in Therapeutics Development 14
Anacor Pharmaceuticals, Inc. 14
Eisai Co., Ltd. 15
Ensemble Therapeutics Corporation 16
F. Hoffmann-La Roche Ltd. 17
JW Pharmaceutical Corporation 18
Thesan Pharmaceuticals, Inc. 19
Hypersensitivity - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AN-3485 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ARN-077 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BD-750 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CWF-0808 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
E-34935 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
E-35018 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OA-1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Peptide to Inhibit Calcineurin for Rheumatoid Arthritis and Hypersensitivity - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RN-486 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Hypersensitivity - Dormant Projects 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for Hypersensitivity, H2 2015 7
Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 14
Hypersensitivity - Pipeline by Eisai Co., Ltd., H2 2015 15
Hypersensitivity - Pipeline by Ensemble Therapeutics Corporation, H2 2015 16
Hypersensitivity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 17
Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H2 2015 18
Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Hypersensitivity - Dormant Projects, H2 2015 40